Hormone-Refractory Prostate Cancer Completed Phase 2 Trials for Docetaxel (DB01248)

Also known as: Hormone Refractory Prostate Cancer Disease / Hormone Refractory Prostate Cancer / Castration-resistant prostate cancer / Hormone refractory prostate cancer (disorder)

IndicationStatusPhase
DBCOND0030169 (Hormone-Refractory Prostate Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00571675A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)Treatment
NCT00675545A Phase II Study of Docetaxel Plus Carboplatin in Chemonaive Hormone-Refractory Prostate Cancer (HRPC) PatientsTreatment
NCT00151073Estramustine, Docetaxel and Zoledronate Treatment in Hormone-Refractory Adenocarcinoma of the ProstateTreatment